CENREVZA Trademark

Trademark Overview

On Wednesday, June 21, 2023, a trademark application was filed for CENREVZA with the United States Patent and Trademark Office. The USPTO has given the CENREVZA trademark a serial number of 98053887. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Thursday, January 11, 2024. This trademark is owned by Gilead Sciences Ireland UC. The CENREVZA trademark is filed in the Pharmaceutical Products category with the following description:

Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for treatment of gastrointestinal diseases and disorders
cenrevza

General Information

Serial Number98053887
Word MarkCENREVZA
Filing DateWednesday, June 21, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateThursday, January 11, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesAntiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for treatment of gastrointestinal diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 25, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGilead Sciences Ireland UC
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCarrigtohill
IE

Trademark Events

Event DateEvent Description
Thursday, January 18, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 11, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, January 11, 2024NON-FINAL ACTION E-MAILED
Thursday, January 11, 2024NON-FINAL ACTION WRITTEN
Thursday, January 11, 2024ASSIGNED TO EXAMINER
Tuesday, July 25, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, June 24, 2023NEW APPLICATION ENTERED

Related Keywords

cenrevza preparations pharmaceutical treatment disorders diseases anti respiratory autoimmune pulmonary kidney